Floatz logo

FILGRASTIM

Indolent Non-Hodgkin Lymphoma

Department of Medical Services Ministry of Public Health of Thailandprotein_peptidePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the Indolent Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Fox Chase Cancer Center
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
PREDNISONE TABLETS
Fate Therapeutics
Phase 2B

View all 34 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →